Revenio Group Oyj

DB:R0V Stock Report

Market Cap: €718.1m

Revenio Group Oyj Valuation

Is R0V undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of R0V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: R0V (€26.92) is trading below our estimate of fair value (€38.59)

Significantly Below Fair Value: R0V is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for R0V?

Key metric: As R0V is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for R0V. This is calculated by dividing R0V's market cap by their current earnings.
What is R0V's PE Ratio?
PE Ratio37.6x
Earnings€19.11m
Market Cap€718.09m

Price to Earnings Ratio vs Peers

How does R0V's PE Ratio compare to its peers?

The above table shows the PE ratio for R0V vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23x
DRW3 Drägerwerk KGaA
7.2x2.0%€798.0m
EUZ Eckert & Ziegler
24.5x5.9%€879.3m
SBS Stratec
33.6x25.4%€336.7m
PUS PULSION Medical Systems
26.7xn/a€134.4m
R0V Revenio Group Oyj
37.6x19.0%€718.1m

Price-To-Earnings vs Peers: R0V is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the peer average (23x).

Price to Earnings Ratio vs Industry

How does R0V's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
R0V 37.6xIndustry Avg. 29.7xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: R0V is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is R0V's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

R0V PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.6x
Fair PE Ratio22.4x

Price-To-Earnings vs Fair Ratio: R0V is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the estimated Fair Price-To-Earnings Ratio (22.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst R0V forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€26.92
€32.75
+21.7%
4.0%€35.00€32.00n/a4
Nov ’25€29.54
€32.33
+9.4%
5.2%€35.00€30.30n/a4
Oct ’25€34.60
€31.83
-8.0%
3.0%€33.00€30.30n/a4
Sep ’25€33.10
€31.83
-3.9%
3.0%€33.00€30.30n/a4
Aug ’25€29.04
€30.33
+4.4%
9.2%€34.00€27.30n/a4
Jul ’25€27.40
€29.05
+6.0%
7.5%€32.00€26.20n/a4
Jun ’25€28.56
€29.33
+2.7%
6.3%€32.00€27.30n/a4
May ’25€25.74
€29.33
+13.9%
6.3%€32.00€27.30n/a4
Apr ’25€25.54
€29.06
+13.8%
5.9%€32.00€27.30n/a5
Mar ’25€25.48
€27.88
+9.4%
5.7%€30.00€25.50n/a4
Feb ’25€24.78
€25.50
+2.9%
6.9%€28.00€23.00n/a4
Jan ’25€26.82
€24.85
-7.3%
8.4%€28.00€22.90n/a4
Dec ’24€23.82
€24.60
+3.3%
8.4%€28.00€22.90n/a4
Nov ’24€21.84
€25.28
+15.7%
7.2%€28.00€23.00€29.544
Oct ’24€20.44
€26.65
+30.4%
5.1%€29.00€25.60€34.604
Sep ’24€23.42
€26.65
+13.8%
5.1%€29.00€25.60€33.104
Aug ’24€31.86
€39.13
+22.8%
7.4%€42.50€35.00€29.044
Jul ’24€31.86
€39.38
+23.6%
6.4%€42.50€36.00€27.404
Jun ’24€30.36
€39.83
+31.2%
4.8%€42.50€38.00€28.563
May ’24€35.82
€40.00
+11.7%
5.4%€43.00€38.00€25.743
Apr ’24€37.80
€40.33
+6.7%
5.1%€43.00€38.00€25.543
Mar ’24€35.40
€40.33
+13.9%
5.1%€43.00€38.00€25.483
Feb ’24€37.48
€41.23
+10.0%
4.2%€43.70€40.00€24.783
Jan ’24€38.70
€41.57
+7.4%
3.8%€43.70€40.00€26.823
Dec ’23€41.70
€41.57
-0.3%
3.8%€43.70€40.00€23.823
Nov ’23€38.90
€41.57
+6.9%
3.8%€43.70€40.00€21.843

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%